The Gen Z Warning: Why Your Youngest Employees Are Sending an Early Signal

Rising prescription costs among 18–25-year-olds aren’t just a pharmacy line item. They’re a preview of what your workforce will cost in a decade and a retention problem hiding in plain sight.

For as long as most benefits strategies have existed, young employees have been treated as the safety valve. Healthy, infrequent utilizers, low-cost by default — the cohort that balances out the higher-cost claims generated by older, more medically complex members. Plan actuaries have built assumptions around this for decades.

That assumption is starting to break.

According to HealthJoy’s 2026 Member Health Goals Report, members aged 18 to 25 saw a 6.87% increase in prescription costs year over year. On its own, that might read as a minor pharmacy trend, but it isn’t. It’s an early signal, and the employers who treat it as a footnote rather than a warning are missing one of the more consequential findings in this year’s data.

The Prescription Burden Is a Symptom, Not the Story

Rising prescription costs among the youngest members of a workforce should prompt a specific question: why are members in their early twenties needing more medication than they did a year ago?

One likely explanation is that chronic conditions are surfacing earlier in this generation than prior actuarial assumptions accounted for. Hypertension, anxiety, or depression requiring medication, early-onset metabolic conditions, and autoimmune diagnoses are appearing in patients in their twenties at rates that would have been unusual a generation ago. The prescription cost increase is not the problem. It’s the visible evidence of a deeper one: a cohort entering the workforce with a health profile that looks meaningfully different from the one benefits strategies were designed around.

This matters because the entire cost logic of a self-funded plan depends on a population pyramid: more low-cost, low-utilization members at the bottom subsidizing the higher costs concentrated at the top. When the base of that pyramid starts generating its own chronic care costs years earlier than expected, the math that has underpinned benefits strategy for decades starts to shift in ways that weren't part of the original actuarial assumptions.

Why Gen Z Is Different — And Why That Difference Compounds

It would be easy to read the prescription cost increase as simply “Gen Z is less healthy than prior generations,” but that framing misses what’s actually driving the trend, and more importantly, misses the part of the problem that's actionable.

The deeper issue is affordability-driven non-adherence. Gen Z members are more likely than older cohorts to ration medication, skip doses, or delay filling a prescription because of cost — not because the medication isn’t covered, but because the out-of-pocket burden, even with coverage, creates a real financial trade-off for someone early in their career. A twenty-three-year-old managing a new anxiety diagnosis or an early blood pressure concern is often also managing student loan payments, rising rent, and a starting salary that leaves little room for an unexpected $50 copay.

This is where the prescription cost data becomes a leading indicator rather than a lagging one. Non-adherence in a 23-year-old doesn’t show up as a claim today. The member simply stops filling the prescription, or fills it inconsistently. What happens next is predictable: the underlying condition progresses without treatment, complications develop that wouldn't have otherwise, and three to five years later, that same employee generates a far more expensive intervention — an ER visit, a hospitalization, a specialist referral — for a condition that could have been managed for a fraction of the cost with consistent, affordable access to medication.

Employers looking at this year’s prescription data and seeing a modest 6.87% increase are seeing the cheapest version of this problem they will ever see. Every year it goes unaddressed, the cost compounds.

The Retention Risk Nobody Is Pricing In

The financial argument for addressing Gen Z prescription affordability is compelling on its own. But there’s a second cost that rarely makes it into a benefits strategy conversation: turnover.

An employee who can’t reliably afford their medication isn’t simply a clinical risk. Affordability-driven non-adherence is also associated with lower retention, particularly among younger workers, who are more likely to job-hop in search of better total compensation and who have less institutional tenure anchoring them to a specific employer. An employee managing a chronic condition who feels like their employer’s health plan isn’t actually making care affordable may be more receptive to a recruiter’s call.

This reframes the prescription affordability conversation entirely. It’s not just a pharmacy benefit design question. It is a talent strategy question, and for employers competing for early-career talent in tight labor markets, it may be one of the more underpriced levers available.

Consider the alternative framing: an employer who solves the affordability gap for a 24-year-old employee managing a new chronic condition isn’t just avoiding a future high-cost claim. They’re signaling, in a concrete and felt way, that the organization invests in its people’s wellbeing from day one. That signal travels. In an era where total compensation conversations increasingly include benefits experience as a differentiator, getting this right is a recruiting and retention asset, not just a cost-containment measure.

What This Means for Benefits Strategy Today

The instinct when prescription costs rise is to look for ways to manage the spend such as tighter formularies, higher cost-sharing, or stricter prior authorization. For an aging or already medically complex population, that instinct sometimes makes sense. For Gen Z, it deserves more caution, because the underlying problem is affordability-driven non-adherence. For a population already rationing medication because of cost, additional cost-sharing is unlikely to reduce spend and may accelerate the escalation pattern this data is warning about.

A more effective approach starts with visibility. Most employers don’t have a clear picture of generic substitution rates on their plan. If that rate is below 85 to 90%, members are very likely paying brand prices for medications that have clinically identical, lower-cost generic alternatives. This is one of the highest-leverage, lowest-friction interventions available — most PBMs can implement automatic substitution prompts or targeted member outreach for the highest-cost brand drugs with generic equivalents, often at no additional cost to the employer.

Beyond substitution, employers should evaluate how affordability information actually reaches younger employees. Gen Z is far more likely to search for a prescription cost comparison online than to call a benefits hotline, which means static, text-heavy benefits communications are unlikely to reach this population at the moment they need the information most — typically while they’re standing at a pharmacy counter, weighing whether to fill a prescription. Integrated pharmacy navigation tools that surface the lowest-cost, clinically appropriate option in real time meet members where the decision is actually being made.

Finally, health literacy deserves more attention than it typically receives in benefits strategy conversations. Many younger employees are navigating a health plan, a pharmacy benefit, and a chronic diagnosis for the first time simultaneously, often without the contextual knowledge older employees have accumulated through years of plan experience. Investing in accessible, digestible education about how their benefits actually work isn’t a soft initiative. It’s a direct lever on whether that 24-year-old fills their prescription this month or decides it can wait.

The Decade-Long Bet

The prescription affordability gap among 18 to 25-year-olds is easy to overlook because the dollar amounts involved today are small relative to other line items on a benefits budget. That’s exactly what makes it dangerous. Small, early signals are the ones organizations are most likely to deprioritize, right up until they compound into something far more expensive.

The employers who treat this finding seriously aren’t just managing a near-term pharmacy cost. They’re making a decade-long bet on the health and loyalty of the employees who will define their workforce in 2030 and beyond. The data says that bet needs to be placed now, while the intervention is still inexpensive and the relationship with these employees is still being formed.

The youngest members of your workforce are sending a signal. The question is whether your benefits strategy is positioned to act on it now or absorb the cost and the turnover later.

This article is part of HealthJoy’s 2026 Member Health Goals Report series, based on self-reported health intent data from 106,768 members collected January 1, 2025 – February 28, 2026.

Download the full 2026 Member Health Goals Report